A new trading day began on Monday, with Trevi Therapeutics Inc (NASDAQ: TRVI) stock price down -8.23% from the previous day of trading, before settling in for the closing price of $11.66. TRVI’s price has ranged from $2.36 to $11.68 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 27.09%. Meanwhile, its annual earnings per share averaged 16.86%. With a float of $80.73 million, this company’s outstanding shares have now reached $121.78 million.
Trevi Therapeutics Inc (TRVI) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Trevi Therapeutics Inc is 33.70%, while institutional ownership is 61.70%. The most recent insider transaction that took place on Oct 07 ’25, was worth 1,032,175. Before that another transaction happened on Oct 03 ’25, when Company’s Officer proposed sale 40,000 for $9.67, making the entire transaction worth $386,716.
Trevi Therapeutics Inc (TRVI) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.13 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.43% during the next five years compared to 27.09% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Here are Trevi Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 22.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.42, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Compared to the last year’s volume of 1.94 million, its volume of 1.45 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 74.69%.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 82.40%, which indicates a significant increase from 32.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.57 in the past 14 days, which was higher than the 0.47 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.18, while its 200-day Moving Average is $6.80. Nevertheless, the first resistance level for the watch stands at $11.46 in the near term. At $12.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.62. If the price goes on to break the first support level at $10.30, it is likely to go to the next support level at $9.91. Now, if the price goes above the second support level, the third support stands at $9.14.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
With a market capitalization of 1.30 billion, the company has a total of 121,777K Shares Outstanding. Currently, annual sales are 0 K while annual income is -47,910 K. The company’s previous quarter sales were 0 K while its latest quarter income was -12,300 K.
